GLOBAL AI IN DRUG DISCOVERY MARKET FORECAST AND ANALYSIS 2025-2032

Report Summary

A STRATEGIC ANALYSIS ACROSS SEGMENTS AND GEOGRAPHIES

*PowerBI dashboard snapshot, Global market, data labels are masked for sample

• The global AI in drug discovery market is experiencing robust expansion, fueled by the escalating demand for innovative drug therapies and the expanding manufacturing capabilities within the life sciences sector. AI technologies, including machine learning and deep learning, are being increasingly applied across various stages of drug discovery, from initial compound screening to predicting success rates in clinical trials. This integration is crucial for identifying novel drug targets and optimizing potential candidates. The market’s growth is further propelled by substantial investments, funding initiatives, and the emergence of numerous startups dedicated to developing advanced AI-powered solutions.
• Additionally, the implementation of AI solutions within the clinical trial process has brought about a transformative shift in the field. This advanced approach is instrumental in addressing traditional obstacles, significantly enhancing productivity and accuracy, and reducing overall development cycle times. The growing popularity of AI among stakeholders in the life sciences industry underscores a rising acknowledgment of the tangible benefits and efficiencies it brings to drug development and clinical validation.
• This market is defined by profound innovation, stemming from the seamless integration of sophisticated algorithms, advanced machine learning techniques, and comprehensive data analytics. These innovations are keenly focused on refining the efficiency and precision of every step in the drug discovery pipeline, spanning from initial target identification to lead optimization and even clinical trial design. Such advancements are playing a pivotal role in substantially curtailing the time and financial investment required to introduce new pharmaceutical products to the market, fundamentally reshaping the landscape of the pharmaceutical industry
• In 2024, the oncology segment commanded the largest portion of the market revenue. This leadership is largely due to cancer’s persistent status as a major global health crisis, which drives significant investment into research and development for effective treatments. AI technologies offer substantial benefits in oncology, including the capacity to analyze intricate datasets, pinpoint new drug targets, and predict how patients will respond to therapies. The integration of AI in oncology has notably accelerated the discovery and development of novel cancer treatments, facilitated personalized medicine approaches, and refined clinical trial designs.
• Meanwhile, the infectious disease segment is projected to exhibit the most rapid growth in the coming years. AI and related platforms, such as the Internet of Things (IoT), are currently being employed to gain a deeper understanding of infectious diseases, their transmission pathways, and infection mechanisms, as well as to enhance vaccine development. These platforms leverage networks of connected devices, including smartphones and various medical instruments, to gather data that can then be used to analyze lifestyle patterns and anomalies relevant to disease study.
• North America stands as a dominant force in the global AI in drug discovery market, holding the largest revenue share. This leadership is driven by a confluence of factors, including substantial investments in healthcare technology, the presence of numerous leading pharmaceutical and biotechnology companies, and robust collaborations between these industry giants and specialized AI technology providers. The region benefits from a highly developed technological infrastructure and a supportive ecosystem for innovation, including world-renowned research institutions. Companies in North America are increasingly leveraging AI to streamline various aspects of drug discovery, aiming to reduce costs, accelerate development timelines, and expedite the introduction of new therapies to market.
• Within North America, the US plays a pivotal role, consistently leading the market in terms of revenue generation and technological advancement. The US is a global hub for AI in drug discovery, characterized by significant R&D investments from both private and public sectors. Major pharmaceutical companies and technology firms based in the US are heavily investing in AI capabilities, fostering a highly competitive and innovative environment. The country benefits from a favorable regulatory environment, with the FDA actively developing frameworks and guidance for AI/ML-based medical products and drug development, which fosters innovation while ensuring safety and efficacy. This progressive regulatory approach, coupled with a high adoption rate of AI-powered tools across the drug development workflow and a considerable number of strategic alliances, firmly positions the US at the forefront of the AI in drug discovery market.
• The European AI in Drug Discovery market presents a vibrant and complex competitive landscape, shaped by a blend of established pharmaceutical powerhouses, innovative AI-first biotechnology companies, and a dynamic ecosystem of emerging startups. While major global tech and pharma companies also have a significant footprint across Europe through their regional operations and partnerships, a distinct competitive environment is fostered by the continent’s strong scientific heritage, supportive government initiatives, and a growing pool of specialized talent.
• A key aspect of this competition is the rise of homegrown European AI biotech firms. Companies like Exscientia and BenevolentAI, both based in the UK, have emerged as global leaders, pioneering AI-driven drug design and target identification, respectively. Their success in bringing AI-designed molecules into clinical trials and forming significant partnerships with major pharmaceutical players highlights their strong competitive position. Beyond these prominent names, other specialized European companies such as Iktos (France), focusing on generative AI for molecular design, and Owkin (France), leveraging federated learning for drug discovery, are actively carving out their niches and collaborating with the broader pharmaceutical industry. This segment of AI-first companies competes not only on technological prowess but also on their ability to attract talent, secure funding, and demonstrate tangible progress in drug pipelines.

*PowerBI dashboard snapshot, Europe market, data labels are masked for sample

• Simultaneously, the competitive landscape is heavily influenced by the proactive strategies of large European pharmaceutical and biotech companies like AstraZeneca, Novartis, Roche, Bayer, and Sanofi. These industry giants are making substantial internal investments in AI R&D, building dedicated AI units, and critically, forming numerous strategic partnerships with AI biotech startups and technology providers. This dual approach allows them to rapidly integrate cutting-edge AI capabilities, enhance their existing drug discovery workflows, and mitigate the risks associated with in-house development. Their sheer R&D spending power, established infrastructure, and global market reach constitute a formidable competitive force within the European market. The ongoing collaborations between these large pharma companies and AI specialists are a crucial element of the competitive dynamic, often defining the pace of innovation and the direction of new drug development in the region.

Table of Content

1. Report Scope
   1. Market Segmentation and scope
   2. Regional Scope
   3. Estimates and forecast timeline
2. Market Research Methodology
   1. Research methodology and design
   2. Sample selection
   3. Reliability and validity
3. Executive Summary
4. Market Analysis
   1. Market size and growth rates
   2. Market growth drivers, market dynamics and trends
   3. Market scenarios and opportunity forecasts
   4. Market constraints and challenges
   5. Industry value chain analysis
   6. Industry analysis – Porter’s
      1. Threat of new entrants
      2. Bargaining power of suppliers
      3. Bargaining power of buyers
      4. Threat of substitutes
      5. Competitive rivalry
   7. PEST analysis
      1. Political/legal landscape
      2. Economic landscape
      3. Social landscape
      4. Technological landscape
5. Market Breakdown – by Component
   1. Introduction
   2. Software
   3. Services
6. Market Breakdown – by Technology
   1. Introduction
   2. Machine Learning
      1. Deep Learning
      2. Supervised Learning
      3. Unsupervised Learning
      4. Reinforcement Learning
      5. Other Machine Learning Technologies
   3. Natural Language Processing (NLP)
   4. Other Technologies
7. Market Breakdown – by Application
   1. Introduction
   2. Target Identification & Validation
   3. Hit Generation/Lead Identification
   4. Lead Optimization
   5. Drug Repurposing/Repositioning
   6. De Novo Drug Design
   7. Preclinical Testing & Approval
   8. Molecular Library Screening
   9. Understanding Disease Mechanisms
   10. Aggregating & Synthesizing Information
   11. Formation & Qualification of Hypotheses
   12. Drug Monitoring
   13. Finding New Diseases Associated Targets & Pathways
8. Market Breakdown – by Therapeutic Area
   1. Introduction
   2. Oncology
   3. Neurodegenerative Diseases
   4. Infectious Diseases
   5. Metabolic Diseases
   6. Cardiovascular Diseases
   7. Inflammatory Diseases
   8. Rare Diseases
   9. Other Therapeutic Areas
9. Market Breakdown – by Deployment Model
   1. Introduction
   2. On-premises
   3. Cloud-based
10. Market Breakdown – by End-User
    1. Introduction
    2. Pharmaceutical & Biotechnology Companies
    3. Contract Research Organizations (CROs)
    4. Academic & Research Institutes
    5. Other End-Users
11. Market Breakdown – by Geography
    1. North America
       1. North America AI in Drug Discovery Market, 2025-2032
       2. North America AI in Drug Discovery Market, by Component
       3. North America AI in Drug Discovery Market, by Technology
       4. North America AI in Drug Discovery Market, by Application
       5. North America AI in Drug Discovery Market, by Therapeutic Area
       6. North America AI in Drug Discovery Market, by Deployment Model
       7. North America AI in Drug Discovery Market, by End-User
       8. North America AI in Drug Discovery Market, by Country
          1. U.S.
          2. Canada
          3. Mexico
    2. South America
       1. South America AI in Drug Discovery Market, 2025-2032
       2. South America AI in Drug Discovery Market, by Component
       3. South America AI in Drug Discovery Market, by Technology
       4. South America AI in Drug Discovery Market, by Application
       5. South America AI in Drug Discovery Market, by Therapeutic Area
       6. South America AI in Drug Discovery Market, by Deployment Model
       7. South America AI in Drug Discovery Market, by End-User
       8. South America AI in Drug Discovery Market, by Country
          1. Brazil
          2. Argentina
          3. Others
    3. Europe
       1. Europe AI in Drug Discovery Market, 2025-2032
       2. Europe AI in Drug Discovery Market, by Component
       3. Europe AI in Drug Discovery Market, by Technology
       4. Europe AI in Drug Discovery Market, by Application
       5. Europe AI in Drug Discovery Market, by Therapeutic Area
       6. Europe AI in Drug Discovery Market, by Deployment Model
       7. Europe AI in Drug Discovery Market, by End-User
       8. Europe AI in Drug Discovery Market, by Country
          1. Germany
          2. France
          3. U.K.
          4. Italy
          5. Spain
          6. Sweden
          7. Belgium
          8. Denmark
          9. Austria
          10. Norway
          11. Switzerland
          12. Netherlands
          13. Russia
          14. Others
    4. Asia-Pacific
       1. APAC AI in Drug Discovery Market, 2025-2032
       2. APAC AI in Drug Discovery Market, by Component
       3. APAC AI in Drug Discovery Market, by Technology
       4. APAC AI in Drug Discovery Market, by Application
       5. APAC AI in Drug Discovery Market, by Therapeutic Area
       6. APAC AI in Drug Discovery Market, by Deployment Model
       7. APAC AI in Drug Discovery Market, by End-User
       8. APAC AI in Drug Discovery Market, by Country
          1. China
          2. Japan
          3. South Korea
          4. India
          5. Australia
          6. Others
    5. Middle East & Africa
       1. MEA AI in Drug Discovery Market, 2025-2032
       2. MEA AI in Drug Discovery Market, by Component
       3. MEA AI in Drug Discovery Market, by Technology
       4. MEA AI in Drug Discovery Market, by Application
       5. MEA AI in Drug Discovery Market, by Therapeutic Area
       6. MEA AI in Drug Discovery Market, by Deployment Model
       7. MEA AI in Drug Discovery Market, by End-User
       8. MEA AI in Drug Discovery Market, by Country
          1. Saudi Arabia
          2. UAE
          3. Israel
          4. Others
12. Competitive Landscape
    1. Global Revenue Share Analysis (%), by Leading Players
    2. North America Revenue Share Analysis (%), by Leading Players
    3. Europe Revenue Share Analysis (%), by Leading Players
    4. APAC Revenue Share Analysis (%), by Leading Players
    5. South America Revenue Share Analysis (%), by Leading Players
    6. MEA Revenue Share Analysis (%), by Leading Players
    7. Key Companies List
       1. Aitia
       2. Atomwise Inc.
       3. BenchSci
       4. BenevolentAI
       5. Berg Health
       6. BioSymetrics, Inc.
       7. Deep Genomics
       8. Exscientia
       9. Google (DeepMind)
       10. IBM
       11. Iktos
       12. Illumina, Inc.
       13. Insilico Medicine
       14. insitro
       15. NVIDIA Corporation
       16. Schrödinger, Inc.
       17. Tempus
       18. Verge Genomics
       19. XtalPi Inc.

Request Sample

Buy Now